安利股份(300218.SZ):與科思創簽訂戰略合作協議 在水性聚氨酯基複合材料方面合作
格隆匯 3 月 25日丨安利股份(300218.SZ)公佈,經友好協商,本着相互尊重、平等和互惠互利的原則,公司於2021年3月25日與科思創(上海)投資有限公司(“科思創”)簽訂了《戰略合作協議》,在水性聚氨酯基複合材料的研發、應用和市場推廣等方面計劃建立合作伙伴關係。
公司於2020年3月開始與科思創開展業務工作,公司使用科思創產品作為部分原材料生產的部分新產品已於2020年7月份量產。雙方將充分利用各自優勢,以適應聚氨酯基複合材料生態環保化的趨勢,共同推進水性聚氨酯基複合材料產業鏈的落地和推廣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.